Arup Roy
Direttore/Membro del Consiglio presso Seraxis Holdings, Inc.
Posizioni attive di Arup Roy
Società | Posizione | Inizio | Fine |
---|---|---|---|
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Direttore/Membro del Consiglio | - | - |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Arup Roy
Statistiche
Distribuzione geografica
Stati Uniti | 3 |
Posizioni
Director/Board Member | 2 |
Settori
Finance | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Seraxis Holdings, Inc.
Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Finance |
Seraxis, Inc.
Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Health Technology |
- Borsa valori
- Insiders
- Arup Roy
- Esperienza